摘要
Abstract
Objective:To assess systematically the effects of Dapagliflozin on blood pressure in patients with type 2 diabetes contrast to the placebo.Method:The databases such as Pubmed,Embase,medline,Cochrane Library,CNKI, WanFang,VIP and CBM were searched to collect the randomized controlled trials(RCTs) of Dapagliflozin versus placebo or other antidiabetic agents.Quality of each RCT was assessed.All outcomes were performed by using Revman 5.2 software. Result:13 RCTs involving 4914 patients were included.The result of Meta-analysis showed that Dapagliflozin relative to placebo or Metformin provided higher reduction in systolic blood pressure [WMD=-3.31,95%CI(-4.10,-2.51),P<0.00001;WMD=-3.01,95%CI(-4.48,-1.44),P=0.0002] and diastolic blood pressure [WMD=-1.50,95%CI(-1.99,-1.01), P<0.00001;WMD=-1.88,95%CI(-2.87,-0.89),P<0.00001];there were no significant differences between them in risk of hypotension(P>0.05).Conclusion:Based on current research evidences,compared with placebo or Metformin,Dapagliflozin lead to a significant higher reduction in either systolic or diastolic blood pressure,the risk of Hypertension is similar with Dapagliflozin relative to the control group.关键词
达格列净/血压/2型糖尿病/系统评价/Meta分析Key words
Dapagliflozin/Blood pressure/Type 2 diabetes/Systematic review/Meta-analysis
